HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis.

Abstract
The influence of the endothelial protein C receptor (EPCR) on the host response to Escherichia coli was studied. Animals were treated with 4 separate protocols for survival studies and analysis of physiologic and biochemical parameters: (1) monoclonal antibody (mAb) that blocks protein C/activated protein C binding to EPCR plus sublethal numbers of E coli (SLEC) (n = 4); (2) mAb to EPCR that does not block binding plus SLEC (n = 3); (3) SLEC alone (n = 4); and (4) blocking mAB alone (n = 1). Those animals receiving blocking mAb to EPCR plus sublethal E coli died 7 to 54 hours after challenge, whereas all animals treated with the other protocols were permanent survivors. Histopathologic studies of tissues from animals receiving blocking mAb plus SLEC removed at postmortem were compared with those animals receiving SLEC alone killed at T+24 hours. The animals receiving the blocking mAb exhibited consumption of fibrinogen, microvascular thrombosis with hemorrhage of both the adrenal and renal cortex, and an intense influx of neutrophils into the adrenal, renal, and hepatic microvasculature, whereas the tissues from animals receiving only sublethal E coli exhibited none of these abnormal histopathologic changes. Compared with the control animals, the animals receiving the blocking mAb exhibited significantly elevated serum glutamic pyruvic transaminase, anion gap, thrombin-antithrombin complex, IL-6, IL-8, and soluble thrombomodulin. The levels of circulating activated protein C varied too widely to allow a clear determination of whether the extent of protein C activation was altered in vivo by blocking protein C binding to EPCR. We conclude that protein C/activated protein C binding to EPCR contributes to the negative regulation of the coagulopathic and inflammatory response to E coli and that EPCR provides an additional critical step in the host defense against E coli. (Blood. 2000;95:1680-1686)
AuthorsF B Taylor Jr, D J Stearns-Kurosawa, S Kurosawa, G Ferrell, A C Chang, Z Laszik, S Kosanke, G Peer, C T Esmon
JournalBlood (Blood) Vol. 95 Issue 5 Pg. 1680-6 (Mar 01 2000) ISSN: 0006-4971 [Print] United States
PMID10688824 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Monoclonal
  • Blood Coagulation Factors
  • Interleukins
  • Receptors, Cell Surface
  • Thrombomodulin
  • Tumor Necrosis Factor-alpha
  • activated protein C receptor
  • alpha 1-Antitrypsin
  • antithrombin III-protease complex
  • Antithrombin III
  • Peptide Hydrolases
  • Leukocyte Elastase
  • Tissue Plasminogen Activator
Topics
  • Animals
  • Antibodies, Monoclonal (pharmacology)
  • Antithrombin III (analysis)
  • Blood Coagulation Disorders (blood, etiology, pathology)
  • Blood Coagulation Factors
  • Escherichia coli Infections (blood, pathology, physiopathology)
  • Interleukins (blood)
  • Leukocyte Elastase (blood)
  • Lung (pathology)
  • Multiple Organ Failure (blood, etiology, pathology)
  • Papio
  • Peptide Hydrolases (analysis)
  • Receptors, Cell Surface (immunology, physiology)
  • Sepsis (blood, microbiology, pathology, physiopathology)
  • Thrombomodulin (blood)
  • Tissue Plasminogen Activator (analysis)
  • Tumor Necrosis Factor-alpha (analysis)
  • Viscera (pathology)
  • alpha 1-Antitrypsin (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: